Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 10 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Pieris Pharmaceuticals Inc | PIRS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.7001 | 06:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.7001 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 3 | 10 | - | 9.31 - 73.60 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:35:02 | 1 | US$ 9.50 | USD |
Pieris Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 958.86M | 98.85M | - | 42.81M | -24.54M | -0.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Pieris Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PIRS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.00 | 10.8299 | 9.511 | 10.08 | 5,844 | -0.2999 | -3.00% |
| 1 Month | 11.13 | 11.18 | 9.31 | 10.19 | 5,566 | -1.43 | -12.85% |
| 3 Months | 14.60 | 15.84 | 9.31 | 13.21 | 211,587 | -4.90 | -33.56% |
| 6 Months | 13.20 | 22.32 | 9.31 | 14.45 | 424,250 | -3.50 | -26.51% |
| 1 Year | 73.60 | 73.60 | 9.31 | 19.76 | 1,295,685 | -63.90 | -86.82% |
| 3 Years | 304.00 | 492.00 | 9.31 | 156.15 | 970,347 | -294.30 | -96.81% |
| 5 Years | 350.40 | 496.00 | 9.31 | 222.31 | 1,208,748 | -340.70 | -97.23% |
Pieris Pharmaceuticals Description
| Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States. |
